Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Its mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. 

Type
Public
HQ
Cambridge, US
Founded
2010
Size (employees)
135 (est)
Website
sagerx.com
Sage Therapeutics was founded in 2010 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Sage Therapeutics

Jeffrey Jonas

Jeffrey Jonas

Chief Executive Officer
Kimi Iguchi

Kimi Iguchi

CFO
Stephen Kanes

Stephen Kanes

Chief Medical Officer
Albert J. Robichaud

Albert J. Robichaud

CSO
Thomas Anderson

Thomas Anderson

Chief Commercial Strategy Officer
Jim Doherty

Jim Doherty

Vice President of Pharmacology, Head of Biology

Sage Therapeutics Office Locations

Sage Therapeutics has an office in Cambridge
Cambridge, US (HQ)
215 First Street
Show all (1)
Report incorrect company information

Sage Therapeutics Financials and Metrics

Sage Therapeutics Financials

USD

Net income (Q3, 2017)

(73.7 m)

EBIT (Q3, 2017)

(74.4 m)

Market capitalization (23-Apr-2018)

5.5 b

Cash (30-Sep-2017)

134.9 m
Sage Therapeutics's current market capitalization is $5.5 b.
Annual
USDFY, 2014FY, 2015FY, 2016

General and administrative expense

9.7 m25.3 m39.4 m

R&D expense

24.1 m69.4 m120.8 m

Operating expense total

33.8 m94.7 m160.2 m

EBIT

(33.8 m)(94.7 m)(160.2 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

4 m6.5 m6.6 m7.1 m8.9 m9 m12.3 m15 m16.1 m

R&D expense

12.9 m18.6 m17.5 m23.6 m26.1 m29.1 m45.2 m55.9 m58.3 m

Operating expense total

16.9 m25.1 m24.1 m30.7 m35 m38.1 m57.5 m70.9 m74.4 m

EBIT

(16.9 m)(25.1 m)(24.1 m)(30.7 m)(35 m)(38.1 m)(57.5 m)(70.9 m)(74.4 m)
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

127.8 m186.8 m168.5 m

Accounts Receivable

35.6 m

Inventories

1.1 m1.7 m5.1 m

Current Assets

128.8 m188.5 m402.6 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

49.1 m136.7 m113.2 m224.2 m204.9 m299.7 m189 m320.1 m145.5 m133.5 m134.9 m

Current Assets

51.5 m137.8 m114.5 m227.5 m207.5 m302.6 m274.1 m434.7 m349 m291.1 m248.3 m

PP&E

69 k134 k269 k285 k249 k865 k959 k1 m1.6 m1.4 m1.9 m

Total Assets

51.7 m138 m115.5 m228.5 m208.4 m303.5 m275.6 m436.3 m351.2 m293.4 m251.1 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(33.8 m)(94.5 m)(159 m)

Depreciation and Amortization

51 k115 k281 k

Inventories

(715 k)(681 k)(3.4 m)

Accounts Payable

441 k2.7 m7.8 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12 m)(21.5 m)(16.9 m)(41.9 m)(65.9 m)(30.5 m)(65.3 m)(103.1 m)(56.8 m)

Depreciation and Amortization

22 k35 k22 k54 k83 k41 k116 k199 k

Accounts Payable

(385 k)(6 k)343 k2.8 m808 k(799 k)941 k116 k8.2 m

Cash From Operating Activities

(10.9 m)(18.4 m)(14.6 m)(33 m)(52.6 m)(27.4 m)(54.1 m)(84.9 m)
USDY, 2017

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information